21.2 Statins (HMG-CoA Reductase Inhibitors) and PCSK9 Inhibitors

Mechanisms of Action and Effects

Statins and PCSK9 inhibitors lower lipid levels through different pathways

Both drug classes ultimately do the same thing: increase the number of LDL receptors on liver cells so more LDL gets pulled out of the bloodstream. But they get there by completely different routes.

Statins (HMG-CoA Reductase Inhibitors)

Statins block the enzyme HMG-CoA reductase, which controls the rate-limiting step of cholesterol synthesis in the liver. When the liver can't make as much cholesterol on its own, it compensates by upregulating LDL receptors on its cell surfaces. Those extra receptors grab more LDL and VLDL from the blood, lowering circulating lipid levels. Common examples include atorvastatin, rosuvastatin, and simvastatin.

PCSK9 Inhibitors

These are monoclonal antibodies (evolocumab, alirocumab) that target the PCSK9 protein. Normally, PCSK9 binds to LDL receptors on liver cells and tags them for degradation. Fewer receptors means less LDL clearance. By blocking PCSK9, these drugs allow LDL receptors to be recycled back to the cell surface instead of being broken down. The result is more available receptors and greater LDL removal from the blood.

Clinical Use and Efficacy

Indications and effectiveness of statins vs. PCSK9 inhibitors

Indications

• Statins are first-line therapy for both primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD). If a patient needs a lipid-lowering drug, statins are almost always where you start.
• PCSK9 inhibitors are reserved for patients who need additional LDL lowering beyond what maximum-dose statins can achieve. Typical candidates include patients with familial hypercholesterolemia or those with established ASCVD whose LDL remains elevated on statin therapy.

Effectiveness

• Statins reduce LDL by approximately 30–50% and significantly lower the risk of cardiovascular events and mortality.
• PCSK9 inhibitors, when added to a statin, can further reduce LDL by 50–60%.
• Combined statin plus PCSK9 inhibitor therapy can lower LDL by up to 75–80% from baseline.
• Clinical trials have shown additional cardiovascular risk reduction when PCSK9 inhibitors are added to statin therapy.

Adverse Effects and Interactions

Side effects and drug interactions to watch for

Statins

• Common side effects: muscle pain or weakness (myalgia), fatigue, GI upset, headache, and mildly elevated liver enzymes (transaminases).
• Rare but serious: Myopathy (significant muscle damage) and rhabdomyolysis (severe muscle breakdown that can lead to kidney failure). Also possible is clinically significant liver injury, though this is uncommon.
• Drug interactions: The risk of muscle-related side effects increases when statins are combined with certain macrolide antibiotics (e.g., clarithromycin), azole antifungals (e.g., itraconazole), and fibrates (e.g., gemfibrozil). These drugs can inhibit statin metabolism, raising statin levels in the blood. Grapefruit juice in large amounts can have a similar effect on certain statins (simvastatin, atorvastatin, lovastatin) by inhibiting CYP3A4 metabolism.

PCSK9 Inhibitors

• Generally well tolerated with a mild side effect profile.
• The most common adverse effect is injection site reactions (pain, redness, itching), since these drugs are given as subcutaneous injections.
• No clinically significant drug interactions have been identified to date.

Nursing Considerations

Assessment, monitoring, and patient education

Nursing Assessment and Monitoring

• Obtain baseline lipid panels and liver function tests (LFTs) before starting therapy. Monitor LFTs periodically, especially during the first year of statin use.
• Ask patients about muscle symptoms at each visit. If a patient reports new or worsening muscle pain, weakness, or tenderness, check a creatine kinase (CK) level to evaluate for myopathy.
• For statins, be aware of the patient's full medication list to identify potential interactions that raise the risk of muscle toxicity.
• Reinforce medication adherence at every encounter. Many patients stop statins because of perceived side effects or because they feel fine and don't think they need the drug.

Patient Education

• Explain that lipid-lowering drugs reduce cardiovascular risk over time, even though the patient won't "feel" the benefit day to day. This helps with long-term adherence.
• Stress the importance of not stopping the medication without talking to the provider first, even if the patient feels well or sees improved lab values.
• Encourage heart-healthy lifestyle changes alongside medication: a diet low in saturated fat, regular physical activity, smoking cessation, and weight management.
• Teach patients to report promptly: unexplained muscle pain or weakness, dark-colored urine, unusual fatigue, or yellowing of the skin or eyes (jaundice).
• For PCSK9 inhibitors specifically, teach proper subcutaneous injection technique, rotation of injection sites, and correct medication storage (typically refrigerated).